Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06733922 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06733922 · ClinicalTrials.gov record · last posted 2026-05-15

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

Study acronym: ELIOS
StatusRecruiting
PhasePhase 4
Started2024-11-27
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.

Protocol amendment history 2 changes detected by DataLookout

2026-05-16
Primary completion pushed: 2027-11-30 → 2028-11-30
2026-05-16
Completion pushed: 2027-11-30 → 2028-11-30
Trial Details
NCT Number NCT06733922
Lead Sponsor Novartis Pharmaceuticals
Conditions Relapsing Remitting Multiple Sclerosis (RRMS)
Enrollment 224 participants
Start Date 2024-11-27
Primary Completion 2028-11-30 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-15